GB2334579B - Treating cancer - Google Patents
Treating cancerInfo
- Publication number
- GB2334579B GB2334579B GB9814545A GB9814545A GB2334579B GB 2334579 B GB2334579 B GB 2334579B GB 9814545 A GB9814545 A GB 9814545A GB 9814545 A GB9814545 A GB 9814545A GB 2334579 B GB2334579 B GB 2334579B
- Authority
- GB
- United Kingdom
- Prior art keywords
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Priority Applications (52)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69907156T DE69907156T2 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
CA002321479A CA2321479A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
US09/622,277 US6521407B1 (en) | 1998-02-18 | 1999-02-18 | Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors |
EP99905087A EP1057032B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
PCT/GB1999/000505 WO1999042836A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
JP2000532726A JP2002504496A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
JP2000532727A JP2002504688A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
JP2000532728A JP2002504354A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
PCT/GB1999/000506 WO1999042821A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
PCT/GB1999/000502 WO1999042090A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AT99905087T ATE238557T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
JP2000532719A JP2002504353A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
AU25379/99A AU743454B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99905081A EP1057027A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU26301/99A AU2630199A (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU25380/99A AU739001B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU25384/99A AU741632B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99905084A EP1057030B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
CA002321481A CA2321481A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99905083A EP1057029B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
DE69907155T DE69907155T2 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
US09/622,577 US6878526B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99905082A EP1057028B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AT99906326T ATE238558T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
CA002321438A CA2321438A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
DE69907152T DE69907152D1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
CA002321480A CA2321480A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AT99905086T ATE238556T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
PCT/GB1999/000500 WO1999042834A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
DE69907153T DE69907153T2 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
AT99905084T ATE238555T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
AT99905082T ATE238553T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
CA002321458A CA2321458A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
JP2000532107A JP2002503822A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
AU25382/99A AU741712B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU25385/99A AU753588B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
JP2000532725A JP2002504687A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
AT99905083T ATE238554T1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
CA002321467A CA2321467A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
CA002321482A CA2321482A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU26300/99A AU749180B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99905086A EP1057031B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
PCT/GB1999/000501 WO1999042835A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
EP99906326A EP1057033B1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
AU25381/99A AU735896B2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
JP2000532712A JP2002504683A (en) | 1998-02-18 | 1999-02-18 | Cancer Treatment |
DE69907151T DE69907151D1 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
PCT/GB1999/000512 WO1999042839A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
PCT/GB1999/000509 WO1999042837A1 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
PCT/GB1999/000503 WO1999042828A2 (en) | 1998-02-18 | 1999-02-18 | Treating cancer |
DE69907154T DE69907154T2 (en) | 1998-02-18 | 1999-02-18 | CANCER TREATMENT |
US10/321,555 US20030134315A1 (en) | 1998-02-18 | 2002-12-18 | Treating cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9803447A GB2334578A (en) | 1998-02-18 | 1998-02-18 | Diagnosis of cancer involving assay of levels of cyclin-dependent kinase (CDK) isoenzymes |
GB9803446A GB2334577A (en) | 1998-02-18 | 1998-02-18 | Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein |
GBGB9812151.0A GB9812151D0 (en) | 1998-06-05 | 1998-06-05 | Treating cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
GB9814545D0 GB9814545D0 (en) | 1998-09-02 |
GB2334579A GB2334579A (en) | 1999-08-25 |
GB2334579B true GB2334579B (en) | 2003-06-04 |
Family
ID=27269218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9814545A Expired - Fee Related GB2334579B (en) | 1998-02-18 | 1998-07-03 | Treating cancer |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2334579B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110196327A (en) * | 2019-05-18 | 2019-09-03 | 贵州医科大学附属医院 | Kit based on genetic variation analysis detection rectum cancer cell drug susceptibility |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017413A1 (en) * | 1993-01-21 | 1994-08-04 | Paracelsian, Inc. | Products for measuring cell growth propensity and methods for their use |
WO1997004316A1 (en) * | 1995-07-20 | 1997-02-06 | Paracelsian, Inc. | Determination of the presence of abnormal cellular proliferation through the detection of one or more cyclin dependent kinases |
WO1997009617A1 (en) * | 1995-09-06 | 1997-03-13 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
WO1997034146A1 (en) * | 1996-03-12 | 1997-09-18 | The General Hospital Corporation | Inhibiting protein interactions |
WO1998013690A1 (en) * | 1996-09-27 | 1998-04-02 | Cold Spring Harbor Laboratory | Oncogene-induced apoptosis in drug-resistant cells |
-
1998
- 1998-07-03 GB GB9814545A patent/GB2334579B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017413A1 (en) * | 1993-01-21 | 1994-08-04 | Paracelsian, Inc. | Products for measuring cell growth propensity and methods for their use |
WO1997004316A1 (en) * | 1995-07-20 | 1997-02-06 | Paracelsian, Inc. | Determination of the presence of abnormal cellular proliferation through the detection of one or more cyclin dependent kinases |
WO1997009617A1 (en) * | 1995-09-06 | 1997-03-13 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
WO1997034146A1 (en) * | 1996-03-12 | 1997-09-18 | The General Hospital Corporation | Inhibiting protein interactions |
WO1998013690A1 (en) * | 1996-09-27 | 1998-04-02 | Cold Spring Harbor Laboratory | Oncogene-induced apoptosis in drug-resistant cells |
Non-Patent Citations (6)
Title |
---|
Annals of Oncology 1995,6,589-593 * |
Anti-Cancer Drugs 1997,8,903-910 * |
CANCER RESEARCH, VOL 57, 1997, LI, W-W ET AL., PAGES 2193-2199. * |
INT. J. CANCER, VOL 68, 1996, LI. W-W. ET AL., PAGES 514-519 * |
INT. J. CANCER, VOL 74, 1997, MAEDA, K. ET AL., PAGES 310-315 * |
J.National Cancer Institute 1996,88(18),1269-1275 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110196327A (en) * | 2019-05-18 | 2019-09-03 | 贵州医科大学附属医院 | Kit based on genetic variation analysis detection rectum cancer cell drug susceptibility |
CN110196327B (en) * | 2019-05-18 | 2022-04-29 | 贵州医科大学附属医院 | Kit for detecting drug sensitivity of rectal cancer cells based on gene variation analysis |
Also Published As
Publication number | Publication date |
---|---|
GB2334579A (en) | 1999-08-25 |
GB9814545D0 (en) | 1998-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104857A3 (en) | New cancer treatments | |
SI1176964T1 (en) | Uses of et743 for treating cancer | |
GB9800942D0 (en) | Well treatment | |
GB9805877D0 (en) | Cancer | |
HK1042847A1 (en) | Bone-pathobolism treating agent | |
GB9816556D0 (en) | Therapy | |
GB9703633D0 (en) | Cancer therapy | |
GB9812519D0 (en) | Treating cells | |
GB9819999D0 (en) | Treatment of cancer | |
EP1018560A4 (en) | Vectors for treating cancer | |
GB9804361D0 (en) | Cancer treatment | |
GB9903035D0 (en) | Treating cancer | |
GB9827102D0 (en) | New cancer treatments | |
GB2334579B (en) | Treating cancer | |
GB9812151D0 (en) | Treating cancer | |
GB9815497D0 (en) | Treatment | |
GB9818524D0 (en) | Inorgasmia treatment | |
GB9818023D0 (en) | Cancer treatment | |
GB9820000D0 (en) | Cancer treatment | |
AU4598100A (en) | Treating cancer | |
GB0007254D0 (en) | Treating cancer | |
GB9914971D0 (en) | Treating cancer | |
GB9828550D0 (en) | Treatment | |
GB2335437B (en) | Treating hide | |
GB9804050D0 (en) | Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application | ||
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20090703 |